RE:RE:RE:RE:RE:Her2-positive brain metastasesYep, I said "operating room." It was the MRI-FUS-microbubble room. Sounds just about as expensive as an operating room. Whatever. Minor detail. Really minor.
Poof's comments about the mice and not eliminating all the tumours is very misleading, and I think purposefully so.
The scientists started treatment on day 21 after the mice were injected in the heart with tumour cells. By day 21 all of the mice had brain tumours. All of the mice were euthanized 14 days later. The 2 control groups were in a bad way and the study, as a comparison between BT2111 (a version of xB3-001), trastuzumab alone, and MTf alone, required all mice to have their treatment started at the same time
The length of the study was the point at which it was unethical to keep the sickest mice alive. In order to analyze and compare all treatments on an equal footing, sadly, even though the Transcend (BT2111) mice were doing well, they also were euthanized, like the rest, on day 35, 14 days after treatment began.
In only 14 days of treatment the BT2111 mice had 68% fewer tumours and the volume of the remaining 32% showed a volume reduction of 57% to 60%. Overall, the BT2111 mice had about 82% less tumour volume than non-BT2111 mice. Here's the equation:
68% + ((100%-68%)*(100%-57%)/100)=81.76%
I think that poof's desire to trip me up prevents him from assessing both the Texas Tech study and the focused ultrasound (FUS) trial in objective ways. He totally misrepresented the results of the Texas Teck study. Any thinking person without an agenda would conclude that the BT2111 mice were almost certainly killed before their time. They had 82% lower tumour volume than the other mice after only 14 days.
poof says that if I was honest I'd report how great that FUS is. There seems to be no doubt that it works. We all recognizes that. But I explained its limitations with respect to brain tumours. It doesn't and can't treat diffuse tumours in the brain. Diffuse tumours are small single to several-cell tumours that can't be detected by any means. xB3 can reach then but FUS, by design, cannot.
FUS takes place in an expensive room with very expensive equipment. Very expensive multiple personnel are required to perform the various FUS steps. And despite all of that, FUS also requires a shot (or infusion) of the drug. xB3 requires only the shot (or infusion) of the drug. Plus, xB3 treats the entire brain and FUS does not.
FUS is not a threat to xB3-001. It's far too expensive.
About the xB3-001 program, it may be shut down or it may not be. If we're staying with WuXi then the required $8 million will stall the program until more money comes in. But xB3-001 could be in the hands of a potential partner under a material transfer agreement, something that poof would never think of. I've been discussing that privately with shareholders for over a year. It forms part of my"Part 2" post that may or may not get posted.
Meanwhile, Bioasis has bigger fish to fry. xB3-004 (IL-1Ra) has far larger potential commercial value than xB3-001. I have already made that case elsewhere so I won't bother rehashing it here. The anti-inflammatory market is over $100 billion annually and is expected to pass $250 billion in the years ahead. Neuroinflammation causes neurodegeneration. It's a monster market, and I think we may have the cleanest way of treating it.
poof's behaviour in these last few posts is embarrassingly awful. We're talking about people's investment here. He's only interested in putting me in my place and not on serving the interests of investors. It's dangerous and it's getting awfully close to a point where it should be reported to regulators.
I don't think it's a coincidence that poof, as a trader, goes all negative on a day when the BTI market is down and he sees a buy opportunity that he can enhance buy scaring even 1 or 2 more investors to dump some shares. He knows that progranulin is on the way. He knows that the Q2 financials are a little over a week away, and that they will resolve some questions. He knows this stock is going to lift again, likely sooner than later.
His behaviour is disgusting.
Texas Tech paper on BT2111. (
click this.